Figure 7

CCR5 Inhibition reduces chronic colitis severity.

(A,B) Colitis severity (weight loss from the day of maraviroc treatment, stool consistency, macroscopic inflammation and colon length) and representative photo of mouse colons after adoptive transfer of CD4⁺ T-cells from the spleens of CCR5^+/+ mice into Rag1^−/− recipient animals (3 × 10⁵ CD45RB^high cells/mouse) alone or after 3 weeks of treatment with maraviroc (50 mg mg/kg/d, 5 days for week). Values indicate mean ± standard error of n = 4 and 6 per group (*P < 0.05). (C) Phenotypic analysis of colonic leukocytes showing the total number of CD45+ cells, total CD4+, CD4+ naïve cells (CD62L^pos/CD44^low) and CD4+ activated/memory cells (CD44^high). (D) Cytokine production by CD4⁺ T-cells obtained from LP of colitic mice alone or treated with maraviroc. Values indicate mean ± standard error of n = 4/group (*P < 0.05).